|  |  |
| --- | --- |
| **Reported by (Name):** | **Bruce Curran** |
| **Organization:**  | **DICOM Working Group-7** |
| **Position Title:** | **AAPM Representative** |
| **Activity:** | **Committee Meetings\_2018** |
| **Meeting Dates:** | **Monthly TCONs, F2F meetings in January, March, May, October, and December. Add’l TCONs and meetings for Brachy, Ion, and Motion Subgroups. I attended January, March, and October meetings in person, phoned in for other meetings.** |
| **Meeting Location:** | **1 meeting / year in Europe, rest in US, generally DC area, ASTRO meeting site, and at Sun Nuclear.** |
| **Payment $:** |  |
| **Reasons for Attending or not Attending** | **Attended as commitments and VCU travel limitations allowed.** |
| **Issues from Previous Meetings or Year:** | **DICOM WG-7 is in the process of a major revision to the Rad Onc DICOM structure, known as “2nd generation DICOM. This will be a major structural overhaul, providing support for new treatment modalities (CyberKnife, GammaKnife, Halycon, and advanced Proton equipment), workflow, structured treatment imaging, and incorporating DICOM changes in segmentation. The effort consists of 9 supplements, of which the first (supplement 147 – Physician Intent and Segmentation) is in final text, additional ones in various development (see minutes of October F2F for full status).** |
| **General Description of Activities of the Organization and/or Meeting:** |  |
| **Issues for AAPM:** | **2nd generation will be a major disruption as manufacturers switch to the new format. AAPM is working to coordinate with IHE-RO, such that testing is done globally to facilitate the transition.** |
| **Budget Request ($):** | **Travel for 1-3 individuals to DICOM F2F meetings. Due to the breadth of working group 7 efforts, frequency of meetings, and need for clinical and software expertise, there are 3 individuals allocated to working group. This allows that AAPM / clinical representation is continuous and covers needed areas of expertise. Current individuals participating on behalf of AAPM are as follows:****Walter Bosch: covers DICOM WG-7 aspects relating to clinical trials, particularly focusing on dose and structure segmentation. Walter is not clinical (though reasonably aware), but has strong IT skills.****Yulong Yu: clinical expertise in areas of brachytherapy and motion compensation. Added to DICOM group during Curran’s absence due to AAPM presidential chain.****Bruce Curran: broad clinical expertise, equipment expertise, and IT skills. Has been vice-chair of WG-7 in the past.** |